PDF(1144 KB)
Mesenchymal stem cell transplantation in the treatment of bronchopulmonary dysplasia: opportunities and challenges
BAO Lei, SHI Yuan
Chinese Journal of Contemporary Pediatrics ›› 2019, Vol. 21 ›› Issue (7) : 619-623.
PDF(1144 KB)
PDF(1144 KB)
Mesenchymal stem cell transplantation in the treatment of bronchopulmonary dysplasia: opportunities and challenges
Bronchopulmonary dysplasia (BPD) is one of the most common chronic lung diseases in neonates especially in preterm infants. It is also the main reason leading to a poor prognosis. The prognosis of the neonates with BPD is unsatisfactory with current treatment strategies. Recent clinical trails have found that mesenchymal stem cell (MSC) transplantation might be effective and promising for treatment of BPD in neonates. This article outlines the characteristics of MSC and the potential mechanisms of MSC transplantation for BPD in vivo, and the safety and feasibility of MSC transplantation in BPD neonates, as well as the challenges in clinical trials on MSC transplantation for treatment of BPD.
Bronchopulmonary dysplasia / Mesenchymal stem cell / Neonate
[1] 李明, 詹成, 代曦煜, 等. 间充质干细胞临床应用的研究进展[J]. 复旦学报(医学版), 2016, 43(4):469-474.
[2] 张梦圆, 王颖翠, 何洁, 等. 脐带间充质干细胞治疗技术的临床研究策略[J]. 西南国防医药, 2018, 28(1):7-9.
[3] Mitsialis SA, Kourembanas S. Stem cell-based therapies for the newborn lung and brain:possibilities and challenges[J]. Semin Perinatol, 2016, 40(3):138-151.
[4] Chang YS, Ahn SY, Sung S, et al. Stem cell therapy for neonatal disorders:prospects and challenges[J]. Yonsei Med J, 2017, 58(2):266-271.
[5] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
[6] Hass R, Kasper C, Böhm S, et al. Different populations and sources of human mesenchymal stem cells (MSC):a comparison of adult and neonatal tissue-derived MSC[J]. Cell Commun Signal, 2011, 9:12.
[7] Li T, Xia M, Gao Y, et al. Human umbilical cord mesenchymal stem cells:an overview of their potential in cell-based therapy[J]. Expert Opin Biol Ther, 2015, 15(9):1293-1306.
[8] El Omar R, Beroud J, Stoltz JF, et al. Umbilical cord mesenchymal stem cells:the new gold standard for mesenchymal stem cell-based therapies?[J]. Tissue Eng Part B Rev, 2014, 20(5):523-544.
[9] Amable PR, Teixeira MV, Carias RB, et al. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly[J]. Stem Cell Res Ther, 2014, 5(2):53.
[10] Fung ME, Thébaud B. Stem cell-based therapy for neonatal lung disease:it is in the juice[J]. Pediatr Res, 2014, 75(1-1):2-7.
[11] Wecht S, Rojas M. Mesenchymal stem cells in the treatment of chronic lung disease[J]. Respirology, 2016, 21(8):1366-1375.
[12] Chang YS, Oh W, Choi SJ, et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats[J]. Cell Transplant, 2009, 18(8):869-886.
[13] Moodley Y, Ilancheran S, Samuel C, et al. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair[J]. Am J Respir Crit Care Med, 2010, 182(5):643-651.
[14] Sung DK, Chang YS, Ahn SY, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury:gene expression profiles and histopathology[J]. PLoS One, 2015, 10(8):e0135574.
[15] Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats[J]. Cell Transplant, 2011, 20(11-12):1843-1854.
[16] van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats[J]. Am J Respir Crit Care Med, 2009, 180(11):1131-1142.
[17] Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia[J]. Thorax, 2013, 68(5):475-484.
[18] Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia:phase 1 dose-escalation clinical trial[J]. J Pediatr, 2014, 164(5):966-972.
[19] Ahn SY, Chang YS, Kim JH, et al. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia[J]. J Pediatr, 2017, 185:49-54.e2.
[20] de la Fuente R, Bernad A, Garcia-Castro J, et al. Retraction:spontaneous human adult stem cell transformation[J]. Cancer Res, 2010, 70(16):6682.
[21] Wagner W. Senescence is heterogeneous in mesenchymal stromal cells:kaleidoscopes for cellular aging[J]. Cell Cycle, 2010, 9(15):2923-2924.
